(NASDAQ: CAPR) Capricor Therapeutics's forecast annual revenue growth rate of 70.91% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Capricor Therapeutics's revenue in 2025 is $17,363,589.On average, 4 Wall Street analysts forecast CAPR's revenue for 2025 to be $3,905,276,055, with the lowest CAPR revenue forecast at $274,246,914, and the highest CAPR revenue forecast at $10,625,239,605. On average, 4 Wall Street analysts forecast CAPR's revenue for 2026 to be $2,692,647,617, with the lowest CAPR revenue forecast at $1,186,117,903, and the highest CAPR revenue forecast at $4,053,826,467.
In 2027, CAPR is forecast to generate $4,954,727,580 in revenue, with the lowest revenue forecast at $2,468,222,226 and the highest revenue forecast at $7,441,232,933.